AVOIDING LUNG COMPLICATIONS FOR PATIENTS POST-SURGERY Improved patient recovery in muscle relaxant reversal drug, according to Specialist anaesthetist-led SNaPP study
With
Professor Kate Leslie AO,
Specialist anaesthetist, Royal Melbourne Hospital &
Honorary Professor, University of Melbourne &
Member, ANZCA Clinical Trials Network
RESEARCH TO PRACTICE SEGMENT
Filmed in Melbourne | October 2026
A “hidden pandemic” of lung complications after surgery has been highlighted by an international study led by Australian researchers that has found how a newer muscle relaxant reversal drug can help improve patient recovery.
The findings of the SNaPP Study (Sugammadex, Neostigmine and Postoperative Pulmonary complications), led by the Department of Critical Care, Melbourne Medical School, University of Melbourne and the Australian and New Zealand College of Anaesthetists (ANZCA) Clinical Trials Network (CTN) were published in The Lancet Respiratory Medicine in June 2026 (https://doi.org/10.1016/S2213-2600(26)00158-X).
Forty-four hospitals and 3500 patients in Australia, New Zealand and Hong Kong were involved in the four-year study, which received $2.9 million from the Medical Research Future Fund (MRFF).
The study’s Principal Investigator, specialist anaesthetist Professor Kate Leslie AO, spoke to Australian Health Journal and said the study answers one of the most hotly debated questions in anaesthesia:
“Lung complications can increase the need for oxygen after surgery and cause distress to patients. By reversing muscle relaxant drugs more effectively, sugammadex helps patients breathe more deeply and prevents collapse of lung tissue,” she said.
Professor Leslie said the trial findings highlighted a “hidden global pandemic” of lung complications for many patients after surgery.
However, while collapse of lung tissue was common, more serious lung complications such as pneumonia were infrequent. There were also no differences in the need for intensive care treatment or length of hospital stay between the two groups of patients studied.
The SNaPP Study recruited patients aged 40 years and older having abdominal or thoracic surgery.
“The study results will have immediate benefits for patients and healthcare systems,” she said.
Source: Adapted from Australian and New Zealand College of Anaesthetists (ANZCA) media release (June 2026)
-
Investments to address health inequities in Prostate Cancer Care
Income, education, geographical location, and discrimination based on ethnicity, race, gender and sexual orientation, are only a fraction of factors that can negatively affect a person’s quality of cancer care. This is defined as the “equity gap” and it’s costing people their lives.
Timed to coincide with World Cancer Day 4th February 2025, Movember announced prostate cancer investment of $5.5 million. Eighteen grants (16 proposals and 2 community development grants) are slated to directly tackle inequities in prostate cancer care. The funding will be over three years with the grants spread across five countries – six in Canada, five in the United Kingdom, three in Australia, three in the United States and one in Ireland – each having a specific focus population and care area.
-
Addressing the perinatal mental health clinician shortage
Perinatal depression and anxiety (PNDA) impacts 100,000 Australians each year, equating to one in five mums and one in ten dads, with PNDA costing Australia $877 million annually. To address the nationwide shortage of specialist perinatal mental health clinicians, Gidget Foundation Australia has partnered with Federation University to launch the Graduate Diploma in Perinatal Mental Health.
-
Report gives insights to clinical trial activity in Australia
Established in 2024, Bellberry is a Adelaide-based national, not-for-profit organisation that provides streamlined scientific and ethical reviews of human research. It is the 2025 winner of the Championing Health Award in the Telstra Best of Business Awards.
Australian Health Journal spoke with Bellberry Limited CEO, Kylie Sproston on the organisation and the findings in activity documented in the Clinical Trial Activity Report (CTAR) 2024.
